The Mexico Long Read Sequencing Market was valued at $4.6 Million in 2024 and projected to reach to $17.3 Million by 2029, representing a compound annual growth rate of 30.0%. Mexico's long read sequencing market is poised for substantial growth over the next five years, driven by increasing adoption of advanced genomic technologies in clinical diagnostics, personalized medicine, and research applications.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Mexico's long read sequencing market is growing at 30% CAGR, significantly outpacing many developed markets. The market is expected to nearly quadruple from $4.6 million in 2024 to $17.3 million by 2029, driven by increasing healthcare investments and genomic research initiatives.
Mexico is emerging as a regional hub for genomic technologies in Latin America. The country's strategic position, growing research infrastructure, and healthcare modernization efforts position it as a key market for long read sequencing adoption across the region.
Mexican healthcare institutions and research centers are increasingly integrating long read sequencing into clinical diagnostics and genomic research programs. This dual adoption across clinical and academic sectors is accelerating market penetration and technology standardization.
Mexico's commitment to advancing genomic medicine and precision healthcare is reflected in growing investments in sequencing infrastructure. Public and private sector initiatives are supporting the adoption of next-generation sequencing technologies in major medical centers.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | DATA ANALYSIS (Workflow) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 32.8% from 2024 to 2029 |
| Largest Segment | RESEARCH USAGE (Usage) |
| Market Size Base Year (Billions) | ~USD 0.76 (2024) |
| Revenue Forecast (Billions) | ~USD 3.13 (2029) |
| Segments Covered | Offering, Technology, Workflow, Application, Usage, End User |
6 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTE | 2.5 | 3.3 | 4.1 | 5.1 | 6.6 | 8.5 | 11.1 | 15.1 | 30 |
| HOSPITALS, CLINICS, AND DIAGNOSTIC LABS | 0.7 | 0.9 | 1.2 | 1.5 | 1.9 | 2.5 | 3.3 | 4.5 | 30.9 |
| OTHER END USER | 0.5 | 0.6 | 0.7 | 0.9 | 1.1 | 1.4 | 1.7 | 2.3 | 25.5 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 1.2 | 1.5 | 1.9 | 2.4 | 3.1 | 3.9 | 5.1 | 7 | 29.8 |
| TOTAL | 4.8 | 6.3 | 7.9 | 9.9 | 12.7 | 16.4 | 21.3 | 28.8 | 29.7 |
Mexico's long read sequencing market was valued at $4.6 million in 2024 and is projected to reach $17.3 million by 2029.
Mexico's long read sequencing market is expected to grow at a compound annual growth rate of 30.0% from 2024 to 2029.
Cancer genomics, rare disease diagnosis, and infectious disease monitoring are the primary clinical applications driving long read sequencing adoption in Mexico.
Mexico's market growth is driven by expanding research infrastructure, increasing pharmaceutical sector engagement, rising precision medicine demand, and growing healthcare investments.
Mexico is positioning itself as a key regional player in Latin America's genomic technology adoption, with significant institutional and pharmaceutical sector investments supporting long read sequencing deployment.
This study on the long-read sequencing market employed secondary sources, directories, and databases to gather pertinent information. To gather and validate important qualitative and quantitative data and evaluate market growth prospects, in-depth interviews were conducted with many primary respondents including key industry participants, subject-matter experts (SMEs), C-level executives from key market players, and industry consultants. After estimating the long-read sequencing market using several research strategies, the size of the final market was obtained by triangulating data from primary research.
The secondary sources referred to for this research study include publications from government sources. These include Nucleic Acids Research, Genome Biology, Nature Reviews Genetics, Nature Methods, Genome Research, International Journal of Genomics, National Human Genome Research Institute (NHGRI), International Chromosome and Genome Society (ICGS), Genome Canada, European Society of Human Genetics (ESHG), Genomics England, Genome British Columbia, Beijing Institute of Genomics, Centre for Cellular & Molecular Biology (CCMB), São Paulo Research Foundation (FAPESP), National Cancer Institute (NCI), European Medicines Agency (EMA), Biotechnology and Biological Sciences Research Council (BBSRC), Organisation for Economic Co-operation and Development (OECD), Population Health Research Institute (PHRI), PubMed, World Bank, and the World Health Organization (WHO), among others. Secondary sources also included corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global long-read sequencing market, which was validated through primary research.
Extensive primary research was conducted after acquiring basic knowledge about the global long-read sequencing market scenario through secondary research. Several primary interviews were conducted with market experts from the supply side, such as C-level and D-level executives, operational managers, marketing & sales managers of key manufacturers, distributors, and channel partners of companies providing long-read sequencing; experts from the demand side, such as personnel from academic & research institutes, hospitals, clinics and diagnostic labs, pharmaceutical & biopharmaceutical industries. These interviews were conducted across six major regions, including North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the long-read sequencing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

To know about the assumptions considered for the study, Request for Free Sample Report
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Long-read sequencing is a type of nucleic acid sequencing that produces genomic data by generating individual reads from single molecules, generally ranging in size from 700 to over 20,000 bases. These fragments are typically derived from "native" molecules, which are directly extracted from biological samples for analysis. The long-read sequencing market encompasses the consumables, instruments, services, and technology associated with long-read sequencing. The long-read sequencing market is defined as solutions including instruments/systems, consumables (kits, reagents, flow cells), and services for long-read sample preparation, sequencing, and data analysis. Long-read software solutions are often provided alongside the instrument/system/platform, hence the software solutions are considered within the instrument segment scope. Other standalone software solutions are provided as data analysis services and are considered within the services segment scope.
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Full forecast, segment splits, and company analysis for all Long Read Sequencing Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report